PRA Group announced the pricing of $400 million in 8.5% senior notes due 2033, offered privately to qualified buyers. The company plans to use the proceeds to repay an equal amount of borrowings under its revolving credit facility, improving its debt structure. The offering is expected to close around October 2, 2026, subject to customary conditions. This move reflects PRA Group's strategy to manage its debt efficiently while continuing its operations in acquiring and collecting nonperforming loans globally.
PRA Group's $400 million senior notes offering is contextually set against Financials-sector activity on Pluang as of Sep 30, 2026 04:22 WIB. Among 85 priced US Financials stocks, 32 rose and 53 fell. Progressive Corp (PGR) gained 1.65% to USD 205.50 with 100% buy orders and a typical hold time of 80 days, contrasting Deutsche Bank AG (DB) which rose 1.63% to USD 36.20 with a 79-day hold, while Lufax Holding Ltd (LU) declined 1.59% to USD 1.24 amid 31% sell orders and a much shorter 12-day hold time on Pluang.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
